论文部分内容阅读
应用Ｓ—Ｐ免疫组化法于石蜡切片对４３例甲状腺癌进行了Ｃ—ｅｒｂＢ—２、Ｐ２１、Ｐ５３、Ｂｃ１—２、Ｃ—ｍｙｃ、Ｐ１６癌基因产物的检测，并以１７例腺瘤、１９例瘤旁正常甲状腺组织作对照。结果：癌组织中均有不同程度１种或１种以上基因产物表达，其阳性表达与腺瘤及瘤旁正常组织间均存在高度显著性差异（Ｐ＜００１）。癌组织中Ｐ２１阳性率最高（６５１％），Ｃ—ｅｒｂＢ—２次之（６２８％）；在乳头状癌中Ｐ２１阳性率最高（８５２％），Ｃ—ｅｒｂＢ—２次之（８１５％）；滤泡状癌中Ｐ５３阳性率最高（６６７％）；而未分化癌中Ｐ５３阳性率最高（８００％）；２例髓样癌Ｐ５３、Ｃ—ｍｙｃ、Ｂｃｌ—２均同时阳性。Ｐ２１和Ｃ—ｅｒｂＢ—２表达率之间呈正相关（Ｐ＞００５）；而与Ｐ５３间呈负相关（Ｐ＜００１）。在淋巴结转移病例中Ｃ—ｅｒｂＢ—２阳性率增高明显（Ｐ＜００５）。本研究结果揭示：１、６种癌基因均参与了甲状腺癌的发生发展过程，有不同的生物学作用，同一癌的发生可为不同基因作用的结果，癌变的发生往往由多种基因相互作用所致；２、Ｃ—ｅｒｂＢ—２、Ｐ２１可能在甲状腺癌尤其是乳头状癌的癌变中起重要作用；而Ｐ５３可能与滤泡癌、髓样?
Immunohistochemical SP method was used to detect the C-erbB-2, P21, P53, Bc1-2, C-myc and P16 oncogenes in 43 cases of thyroid cancer and 17 cases of adenomas. In 19 cases, normal thyroid tissue next to the tumor was used as a control. RESULTS: The expression of one or more gene products in different degrees was detected in cancer tissues. There was a highly significant difference between positive expression and adenoma and adjacent normal tissues (P<0.01). The positive rate of P21 in cancer tissues was the highest (65.1%), followed by C-erbB-2 (62.8%); the positive rate of P21 in papillary carcinoma was the highest (85. 2%), C-erbB-2 times. (815%); P53 positive rate was highest in follicular carcinoma (667%); P53 positive rate was highest in undifferentiated carcinoma (800%); 2 cases of medullary carcinoma P53, C-myc Both Bcl-2 are positive at the same time. There was a positive correlation between P21 and C-erbB-2 expression rates (P>005); however, there was a negative correlation between P21 and P53 (P<001). The positive rate of C-erbB-2 in lymph node metastasis was significantly higher (P < 0.05). The results of this study reveal that: 1. The six oncogenes are involved in the development of thyroid cancer and have different biological effects. The occurrence of the same cancer may be the result of different genes. The occurrence of cancer often involves multiple gene interactions. Cause; 2, C-erbB-2, P21 may play an important role in the carcinogenesis of thyroid cancer, especially papillary carcinoma; and P53 may be associated with follicular carcinoma, myeloid?